Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revised CDRH Modular Guidance Will Include Panel-Track Supplements

This article was originally published in The Gray Sheet

Executive Summary

FDA will extend its modular premarket submissions program to PMA panel-track supplements, according to the Center for Devices & Radiological Health's Joanne Less

You may also be interested in...



Modular PMA Review Times Go Up; FDA Proposes Performance Goals

FDA would like to incorporate Medical Device User Fee & Modernization Act performance goals into revised guidance for the modular PMA program

Modular PMA Review Times Go Up; FDA Proposes Performance Goals

FDA would like to incorporate Medical Device User Fee & Modernization Act performance goals into revised guidance for the modular PMA program

Third-Party 510(k) Reviews Increasingly Time-Consuming For CDRH – Kahan

CDRH is hosting a face-to-face training session for "accredited persons" as part of ongoing efforts to improve its third-party review program

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel